Ntroduction - Exchange Introductions - Only proven way to promote your career

Jurassic 5 - "What's Golden" acapella over Common Market - "Connect For" instrumental Both songs are mad dope to begin with, but I was trying to share this with ya. Download a full mix of mash ups on Sabzi beats here free: hazeymorning.blogspot.com

Leveraged loan volume, default rates, yields and returns are featured in this monthly video analysis of the US leveraged loan market. Also: a detailed look at the burgeoning CLO market. Connect with LCD Download the slides for this video (free) at Slideshare.net! ow.ly Connect with LCD Facebook: www.lcdcomps.com Like LCD on Facebook for monthly analysis on LBO/Private equity stats, as well as Default/Restructuring analysis. LinkedIn: www.lcdcomps.com There's almost 6000 market contacts in LCD's Leveraged Loan Group Twitter: www.twitter.com News, commentary, other leveraged finance info Web: www.lcdcomps.com

www.steinarknutsen.com Twitter and Facebook can help grow your business online. These are the two most popular social media marketing networks and if use appropriately you can effectively find and engage customers in conversation. Maybe you want to provide customer support or communicate new offers in a timely basis. The key is these platforms offer a place to listen to your market and engage in dialogue to better understand the needs of your new and existing customers. In this video I highlight the key considerations such as - Find prospects in your niche market - Connect with existing customers - Bring personality to your business - Share time-sensitive news & offers - Drive traffic back to your website - Deliver responsive customer service - Monitor competitive activity

Market, Connect, Sell! Get off to a fast start in 2012 by exhibiting your new product lines at the 3 biggest business days in racing—the PRI Trade Show! 40000 buyers come...shop...buy! Go where the opportunities are! Get new business, pre-qualified leads, national distribution, international expansion and increased market share!

Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

VIERA Connect Apps and optional accessories can be easily purchased from VIERA Connect Market right on the VIERA screen. The operating procedure is shown here. *This is the European version. Check out this site for details -- panasonic.net VIERA Global Site panasonic.net

beyond Profiles weekly look at the market. Connect with us www.beyondprofile.com twitter.com

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

This is our Christmas training day, we had a lot of fun and we want to share it with you =) Merry Christmas and Happy New Year for everyone =) Music: Common Market - Connect Four